Institut de Recherches Cliniques de Montreal

Quick facts

Marketed products

• Atenolol Thiazide · Cardiovascular
  Atenolol Thiazide is a combination drug that reduces blood pressure by blocking beta-adrenergic receptors (atenolol) and promoting sodium and water excretion through the kidneys (thiazide diuretic).
• Candesartan Thiazide · Cardiovascular
  Candesartan thiazide is a combination drug that blocks angiotensin II receptors to lower blood pressure while a thiazide diuretic enhances sodium and water excretion.
• Detemir or Glargine · Diabetes
  Detemir and Glargine are long-acting basal insulin analogs that bind to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues.
• Thiazide Candesartan

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Institut de Recherches Cliniques de Montreal portfolio CI brief
• Institut de Recherches Cliniques de Montreal pipeline updates RSS